751621
Last Update Posted: 2014-04-02
Recruiting has ended
All Genders accepted | 2 Years-65 Years |
40 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)
This study is a continuation of the study ZLB06_001CR with the objective of assessing efficacy, tolerability, safety of IgPro, as well as long-term health-related quality of life in patients with PID.
Eligibility
Relevant conditions:
Primary Immunodeficiency (PID)
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov